Loading
institutionsInstitution
IRCCS Ospedale San Raffaele
Milan's research hospital known for engineered T-cell therapies, gene therapy, high-volume pancreatic surgery and HER2 breast cancer trials.
Also called: San Raffaele HospitalOSRUniversità Vita-Salute San Raffaele
Overview
Ospedale San Raffaele is a private IRCCS research hospital with its own university and a strong gene and cell therapy tradition through the San Raffaele Telethon Institute for Gene Therapy. Fabio Ciceri's haematology and transplant unit and Chiara Bonini's experimental haematology laboratory developed suicide-gene-modified donor lymphocytes and TCR-edited T cells, Luca Gianni's breast oncology programme led the NeoSphere trial of dual HER2 blockade with pertuzumab and trastuzumab, and Massimo Falconi's pancreatic surgery unit is among Europe's highest-volume centres. The hospital runs neuro-oncology, urology, radiotherapy and a phase 1 unit, and pathology under Claudio Doglioni supports genomics-driven trials.
Location
Milan, IT
Type
hospital · Università Vita-Salute San Raffaele
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#179 · 30 points (0 Newsweek + 0 NCI + 30 from 15 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to IRCCS Ospedale San Raffaele, including child institutions. 399 works · 5,644 citations · 71% open access · 12% clinical trials · 4% reviews.
Oncology works per year
662022
1022023
732024
1072025
512026
Most works
- Giampaolo Bianchini33 works
- Chiara Bonini24 works
- Massimo Falconi20 works
- Matteo Dugo19 works
- Maria Chiara Tisi17 works
- Michele Reni16 works
- Giovanni Paolino15 works
- Luigi Naldini15 works
- Fabio Ciceri14 works
- Luca Gianni13 works
Most cited
- Engineered T-cell and gene therapy
- Haematology and transplantation
- Pancreatic surgery
- HER2-positive breast cancer trials
- Neuro-oncology
Andrea Necchi
Head of Genitourinary Medical Oncology, IRCCS San Raffaele Hospital; Professor, Vita-Salute San Raffaele University
Urothelial cancerNeoadjuvant immunotherapyBladder preservation
Led PURE-01, the first neoadjuvant pembrolizumab trial in bladder cancer, and now leads bladder-preserving immunotherapy studies.
Andrés J. M. Ferreri
Head of the Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milan
Primary CNS lymphomaExtranodal lymphomasHigh-dose methotrexate regimens
Led the IELSG trials that made MATRix induction and consolidation the standard for primary CNS lymphoma.
Gianvito Martino
Scientific Director (Direttore Scientifico)
NeuroscienceNeuroimmunologyResearch leadership
Neurologist and neural stem cell researcher who serves as Scientific Director of IRCCS Ospedale San Raffaele in Milan.
Marco Centenari
Representative of IRCCS Ospedale San Raffaele to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Marco Centenari represents IRCCS Ospedale San Raffaele in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.
Similar pages
- InstitutionSeoul St. Mary's Hospital
Shares Allogeneic (off-the-shelf) cell therapy, Robotic & minimally invasive surgery, CAR-T cell therapy, Acute lymphoblastic leukaemia.
- PersonStephen J. Forman
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- CompanyAllotera Therapeutics (formerly Wugen)
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- PersonPhilip D. Greenberg
Shares TCR-T cell therapy, CAR-T cell therapy, Acute myeloid leukaemia, Pancreatic ductal adenocarcinoma.
- TargetCD7
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- InstitutionPeking University People's Hospital
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- CompanyImugene
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute lymphoblastic leukaemia.
- InstitutionChristian Medical College, Vellore
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
cancers
fronts
technologies
targets
drugs
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)